Virbac’s update on shares and voting rights
On August 31, 2024, Virbac released an update on its capital structure—how many shares exist and how many votes those shares carry. It’s a snapshot of ownership and influence. It’s also a window into how the company runs itself, from annual meetings to long-term strategy.
The numbers that matter
Start with the base: Virbac reported 8,458,000 shares making up its share capital as of August 31, 2024. From there, two voting-rights figures set the tone for governance. The gross total of voting rights stands at 12,776,794. This figure represents all theoretical votes attached to shares before any deductions. It’s the ceiling—the maximum count used as a reference point for shareholder power.
Gross vs. net: what changes—and why it matters
Next comes the number that’s closer to everyday reality: the net total of voting rights is 12,693,388. The net figure removes shares that don’t confer voting rights, providing a more accurate view of who can actually vote. Two numbers, one purpose: to show potential influence (gross) and effective influence (net). That distinction helps shareholders gauge their impact ahead of meetings, resolutions, and board elections, where every counted vote shapes outcomes.
Clear disclosure, plain and simple
Virbac’s decision to share these details aligns with its standing as a company listed on Euronext Paris (compartment A). Regular disclosure isn’t just good practice; it’s part of maintaining a level playing field for investors. By publishing the share count and both voting-rights totals, the company makes it easier for you to assess dilution, voting concentration, and how changes over time might affect control. Transparency doesn’t settle every question, but it gives everyone the same baseline facts.
Shareholder engagement starts with information
Open communication builds trust. When a company consistently reports on shares and voting rights, it supports a healthier dialogue with shareholders large and small. It helps you prepare for key votes, understand the mechanics behind governance, and track how the balance of power can shift. That foundation supports better questions, clearer expectations, and sturdier decision-making—on both sides of the table.
Innovation stays in view
Numbers matter, but they sit alongside the work that defines Virbac’s day-to-day: animal health. The company continues to focus on developing effective treatments and advancing veterinary care. That commitment isn’t separate from the capital picture; it complements it. Strong governance supports consistent execution, and consistent execution supports the mission. The throughline is steady: invest in the core work, communicate clearly, and let shareholders see the road ahead.
Looking ahead
As market conditions shift, these disclosures will keep serving as guideposts. The share count anchors ownership. The gross and net voting rights frame decision-making power. Together, they help investors and customers track how Virbac intends to navigate what’s next—by combining transparent reporting with ongoing work in animal health. One step at a time, with the same two numbers in view.
Frequently Asked Questions
What did Virbac report about its share capital on August 31, 2024?
Virbac reported that its share capital consisted of 8,458,000 shares as of August 31, 2024.
What are the gross and net totals of voting rights?
The gross total of voting rights is 12,776,794, and the net total—after excluding shares without voting rights—is 12,693,388.
Why are there two voting-rights figures?
The gross figure reflects the theoretical maximum voting power attached to all shares, while the net figure shows the actual votes that can be cast after removing non-voting shares. The net total is the practical number for governance decisions.
How does this disclosure help shareholders?
It provides a clear view of ownership and influence, helping shareholders prepare for meetings, evaluate voting power, and follow changes in control over time.
Where does this fit in Virbac’s broader strategy?
Transparent reporting on shares and voting rights sits alongside Virbac’s focus on advancing animal health. Together, they support steady execution, informed decisions, and a consistent view of the company’s direction.
